Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.73 Analyst target: $3.92 Upside: 439.68%
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.